New Daily Persistent Headache
New daily persistent headache (NDPH) is a distinctive primary headache disorder defined by the abrupt onset of a daily headache that is continuous and unremitting from the moment it begins. The patient can typically pinpoint the exact date the headache started. NDPH is one of the most treatment-resistant headache disorders. It may have features mimicking chronic migraine or chronic TTH, but the defining characteristic is the daily-from-onset pattern with a clearly remembered start date. Secondary causes must be exhaustively excluded before making this diagnosis.
Bottom Line
- Defining feature: Daily and continuous headache from onset, with a clearly recalled and identifiable start date. The patient can tell you exactly when the headache began.
- ICHD-3: Headache present daily and unremitting within 24 hours of onset, for >3 months
- Two prognostic subtypes: Self-limiting (resolves within months to 2 years) and refractory (persists for years despite treatment). No way to predict which subtype at onset.
- Diagnosis of exclusion: Must rule out medication overuse, CSF pressure disorders, cerebral venous thrombosis, and other secondary causes first
- Treatment is empiric and often disappointing. No RCTs exist. Try standard migraine or TTH preventives based on the headache phenotype.
- Triggers: Often follows a viral illness, stressful life event, or surgical procedure. EBV and other infections are implicated.
ICHD-3 Criteria (4.10)
- A. Persistent headache fulfilling B and C
- B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours
- C. Present for >3 months
- D. Not better accounted for by another ICHD-3 diagnosis
The headache itself may have migraine-like or TTH-like features. The phenotype is not what defines NDPH — it is the temporal pattern (daily from onset) that is diagnostic.
Clinical Features
| Feature | Details |
|---|---|
| Onset | Abrupt onset of daily headache. Patient can name the exact date. Often starts as a specific headache that simply never goes away. |
| Demographics | Equal sex ratio (unlike migraine). Can occur at any age; two peaks — adolescents/young adults and middle-aged adults. |
| Phenotype | ~60% migraine-like (unilateral, pulsating, photo/phonophobia); ~40% TTH-like (bilateral, pressing). Both phenotypes persist daily from onset. |
| Intensity | Variable. May be moderate at baseline with more severe exacerbations. Some patients report constant severe headache. |
| Prior headache history | May or may not have pre-existing migraine or TTH. The NDPH represents a new, different headache that begins de novo. |
Triggering Events
- Viral illness: 30-50% of cases are preceded by a flu-like or upper respiratory illness. EBV, HSV, CMV, and other viruses have been implicated.
- Stressful life event: ~15-20% report a major life stressor preceding onset
- Surgical procedure: Particularly intubation or procedures in Trendelenburg position (may cause occult CSF leak or cervical strain)
- No identifiable trigger: ~30% have no clear precipitant
Differential Diagnosis
Must Exclude Before Diagnosing NDPH
- Medication overuse headache: If patient began using acute medications frequently after the headache started, MOH may be maintaining it. Withdraw and reassess.
- Spontaneous intracranial hypotension: Orthostatic component may be subtle or lost over time. MRI brain with contrast (pachymeningeal enhancement) is mandatory.
- Cerebral venous sinus thrombosis: MRV should be part of the initial workup
- Elevated ICP (IIH): Check for papilledema; LP if suspected
- Cervical artery dissection: If neck pain preceded the headache onset
- Sphenoid sinusitis: Can cause constant headache mimicking NDPH. CT sinuses if nasal symptoms.
- Chronic meningitis: Low-grade infectious or inflammatory meningitis. CSF analysis if persistent headache + any systemic features.
- Post-infectious: COVID-19-associated persistent daily headache is increasingly recognized and may overlap with NDPH phenotypically.
Recommended Initial Workup for Suspected NDPH
- MRI brain with contrast (exclude mass, pachymeningeal enhancement of SIH, pituitary pathology)
- MRV (exclude venous sinus thrombosis)
- ESR, CRP (exclude inflammatory/vasculitic cause)
- Consider LP: CSF opening pressure (exclude high or low pressure), CSF composition (exclude chronic meningitis)
- Detailed headache diary documenting medication use (exclude MOH)
Proposed Pathophysiology
- Post-infectious neuroinflammation: Viral triggers may activate glial cells and pro-inflammatory cytokines (TNF-α, IL-6) in the trigeminal nucleus and central pain pathways, leading to persistent central sensitization
- Cervical joint hypermobility: May contribute to cervicogenic component in some patients
- Autoimmune mechanism: Some investigators have proposed autoantibodies against neural targets, analogous to autoimmune encephalitis, though this remains speculative
- Persistent glial activation may explain why the headache is resistant to conventional treatments that target neuronal mechanisms
Treatment
There are essentially no high-quality randomized controlled trials dedicated to NDPH. Treatment recommendations rest largely on small/pilot studies, case series, expert opinion, and extrapolation from chronic migraine or chronic TTH evidence.
Prognostic Subtypes
| Subtype | Course | Estimated Frequency |
|---|---|---|
| Self-limiting | Resolves spontaneously within months to 2 years, often without treatment | ~40-50% |
| Refractory | Persists for years despite aggressive treatment with multiple preventive classes | ~50-60% |
Treatment Approach
| Strategy | Agents / Approach | Notes |
|---|---|---|
| Migraine-like phenotype | Amitriptyline, topiramate, venlafaxine, beta-blockers, CGRP mAbs, OnabotulinumtoxinA | Trial each for adequate duration. Response rates are lower than in primary migraine. CGRP mAbs and Botox are used off-label. |
| TTH-like phenotype | Amitriptyline, nortriptyline, mirtazapine | TCAs are the most commonly used agents |
| Nerve blocks | GON block every 2-4 weeks | Worth trying in all phenotypes. May provide temporary relief even in refractory cases. |
| Muscle relaxants | Tizanidine 2-8 mg, cyclobenzaprine 5-10 mg | Adjunct for patients with cervical muscle tension component |
| Anti-inflammatory approach | Doxycycline 100 mg BID (anti-inflammatory effect), naproxen 250-500 mg BID scheduled | Case reports suggest benefit in post-infectious NDPH, possibly by targeting neuroinflammation. Time-limited trial (4-8 weeks). |
| Non-pharmacologic | CBT, biofeedback, physical therapy, exercise | Important adjuncts. CBT addresses pain coping and comorbid mood disorders. |
Practical Approach to NDPH
- Exhaustive exclusion of secondary causes (MRI, MRV, consider LP, labs)
- Classify the phenotype (migraine-like vs TTH-like) and treat accordingly
- Withdraw overused medications if MOH component is present
- Sequential preventive trials: Amitriptyline → topiramate → venlafaxine → CGRP mAb → OnabotulinumtoxinA (if chronic migraine-like). Each for adequate dose and duration before declaring failure.
- Add nerve blocks as adjunct throughout
- Behavioral therapy and exercise from the start
- Counsel on prognosis: Honest discussion that some patients improve over 1-2 years while others are refractory. Realistic goals (improved function, reduced severity) rather than complete resolution.
References
- Rozen TD. New daily persistent headache: an update. Curr Pain Headache Rep. 2014;18(7):431.
- Robbins MS, et al. Treatment of new daily persistent headache. Curr Treat Options Neurol. 2010;12(1):1-13.
- Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22(1):66-69.
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
- Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain. 2019;20(1):80.
